Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Gold Trust (IAU) vs Mesoblast Limited (MESO) Price & Performance

iShares Gold TrustTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

iShares Gold Trust vs Mesoblast Limited — how do they compare? iShares Gold Trust trades at $76.84, while Mesoblast Limited trades at $16.34 (market cap $2.17B). Which is the better fit depends on your goals.

IAUMESO
Sector
Commodities - Metals/AgricultureTechnology
52-Week High
$101.57$20.96
52-Week Low
$61.62$12.88
Market Cap
$2.17B
Enterprise Value
$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Gold Trust

IAU, the iShares Gold Trust ETF, trades at $75.35, down 0.2% on the day. Technical indicators are bearish, with moving averages signaling a downtrend and key support at $75. Recent news highlights institutional activity, including a new position by Eurizon Asset Management Hungary Ltd. in Q1 2026, while broader gold sentiment is pressured by expectations of sustained higher interest rates.

The outlook for IAU is influenced by macroeconomic factors affecting gold. Higher-for-longer interest rate expectations from the Fed (WSJ, 2026-07-19) pose a headwind, but structural central bank buying (WSJ, 2026-07-16) offers support. The primary risk is gold's sensitivity to monetary policy, while the opportunity lies in its role as a hedge amid economic uncertainty.

Mesoblast Limited

MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.

Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Gold Trust

IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.

Read more on IAU

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO